Organisation paid for research Program year 2025 Source: CMS Open Payments

Innovative Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$17,289,288

2,015 payments

Through program year 2025, Innovative Clinical Research Inc is reported as receiving $17,289,288 in research payments, across 2,015 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,032,957 724
2024 Research $1,068,119 263
2023 Research $241,304 66
2022 Research $5,160,365 154
2021 Research $2,052,274 245
2020 Research $2,518,138 327
2019 Research $3,216,131 236

Breakdown

Who paid Research payments · program years 2019–2025
  1. ITI, Inc. $6,523,395 838 payments
  2. Allergan Inc. $2,358,977 249 payments
  3. Teva Pharmaceuticals USA, Inc. $2,085,782 187 payments
  4. Vanda Pharmaceuticals Inc. $1,850,252 20 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,378,462 32 payments
  6. AbbVie, Inc. $849,538 133 payments
  7. Indivior Inc. $525,260 155 payments
  8. Sage Therapeutics, Inc. $420,432 121 payments
  9. Roche TCRC, Inc. $412,900 53 payments
  10. Biogen, Inc. $283,663 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $3,683,855 64 payments
  2. Iti-007-451 $2,272,719 645 payments
  3. Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $1,845,552 19 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,372,598 73 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $683,496 34 payments
  6. A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder $620,601 17 payments
  7. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $429,747 51 payments
  8. Protocol 331-201-00080 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $420,359 1 payment
  9. The Effect of 24Week Treatment With Basmisanil on Cognitive Impairment Associated With Schizophrenia $412,900 53 payments
  10. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $398,446 52 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record